IMDX (Insight Molecular Diagnostics) Ending Cash Position: $29.36 Mil (As of Mar. 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $5.07
GF Value $1.25
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Ending Cash Position?

Insight Molecular Diagnostics IMDX +4.10% 49 Ending Cash Position is $29.36 Mil as of Mar. 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.25 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Insight Molecular Diagnostics's Ending Cash Position for the quarter that ended in Mar. 2026 was $29.36 Mil.

Insight Molecular Diagnostics's quarterly Ending Cash Position declined from Sep. 2025 ($20.21 Mil) to Dec. 2025 ($12.92 Mil) but then increased from Dec. 2025 ($12.92 Mil) to Mar. 2026 ($29.36 Mil).

Insight Molecular Diagnostics's annual Ending Cash Position declined from Dec. 2023 ($11.13 Mil) to Dec. 2024 ($10.34 Mil) but then increased from Dec. 2024 ($10.34 Mil) to Dec. 2025 ($12.92 Mil).

Insight Molecular Diagnostics Ending Cash Position Related Terms

Insight Molecular Diagnostics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics Ending Cash Position Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.31 23.20 11.13 10.34 12.92

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.73 25.99 20.21 12.92 29.36
IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Insight Molecular Diagnostics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=10.336+2.583
=12.92

Insight Molecular Diagnostics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=12.919+16.436
=29.36

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $29.36 Mil mean?
Insight Molecular Diagnostics (IMDX) has a Ending Cash Position of $29.36 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Insight Molecular Diagnostics and its competitors.
Is Insight Molecular Diagnostics' Ending Cash Position too high?
Insight Molecular Diagnostics' current Ending Cash Position is $29.36 Mil. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Ending Cash Position compare to XGN and BDSX?
Insight Molecular Diagnostics' Ending Cash Position of $29.36 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Ending Cash Position is $29.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $5.07 — trading 305.6% above its estimated fair value. The current Ending Cash Position is $29.36 Mil. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Ending Cash Position is $29.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.07 is trading 305.6% above its estimated GF Value™ of $1.25. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • Ending Cash Position: $29.36 Mil
  • GF Value™: $1.25 vs. price of $5.07 (305.6% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.07
Price
$1.25
GF Value